Fli1 deficiency contributes to the suppression of endothelial CXCL5 expression in systemic sclerosis

Archives of Dermatological Research

Volumn 306, Issue 4, 2014, Pages 331-338

  Ichimura, Yohei ^a   Asano, Yoshihide ^a   Akamata, Kaname ^a   Takahashi, Takehiro ^a   Noda, Shinji ^a   Taniguchi, Takashi ^a   Toyama, Tetsuo ^a   Aozasa, Naohiko ^a   Sumida, Hayakazu ^a   Kuwano, Yoshihiro ^a   Yanaba, Koichi ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Sato, Shinichi ^a   Kadono, Takafumi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Angiogenesis; CXCL5; Digital ulcer; Endothelial cells; Fli1; Systemic sclerosis

Indexed keywords

EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; MESSENGER RNA; TRANSCRIPTION FACTOR FLI 1; CXCL5 PROTEIN, HUMAN; FLI1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADULT; AGED; ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; ENDOTHELIUM CELL; FEMALE; FINGER ULCER; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; KNOCKOUT MOUSE; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SKIN BLOOD VESSEL; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; ANIMAL; BIOSYNTHESIS; BLOOD; CELL CULTURE; DEFICIENCY; DIFFUSE SCLERODERMA; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; RNA INTERFERENCE;

AGED; ANIMALS; CELLS, CULTURED; CHEMOKINE CXCL5; ENDOTHELIAL CELLS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEIN C-FLI-1; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SCLERODERMA, DIFFUSE;

EID: 84900816826     PISSN: 03403696     EISSN: 1432069X     Source Type: Journal    
DOI: 10.1007/s00403-013-1431-9     Document Type: Article

References (34)

1. (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum 23: 581-590
2. Asano Y, Czuwara J, Trojanowska M (2007) Transforming growth factor-b regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem 282:34672-34683 (Pubitemid 350232412)
3. Asano Y (2010) Future treatments in systemic sclerosis. J Dermatol 37:54-70
4. Asano Y, Stawski L, Hant F, Highland K, Silver R, Szalai G et al (2010) Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 176:1983-1998
5. Beck GC, Yard BA, Breedijk AJ, Van Ackern K, Van Der Woude FJ (1999) Release of CXC-chemokines by human lung microvascular endothelial cells (LMVEC) compared with macrovascular umbilical vein endothelial cells. Clin Exp Immunol 118:298-303 (Pubitemid 29519263)
6. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD et al (2000) CXC chemokines in angiogenesis. J Leukoc Biol 68:1-8
7. Bolster MB, Ludwicka A, Sutherland SE, Strange C, Silver RM (1997) Cytokine concentrations in bronchoalveolar lavage fluid of patients with systemic sclerosis. Arthritis Rheum 40:743-751
8. Chandrasekar B, Melby PC, Sarau HM, Raveendran M, Perla RP, Marelli-Berg FM et al (2003) Chemokine-cytokine cross-talk. The ELR + CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF- jB pathway. J Biol Chem 278:4675-4686 (Pubitemid 36800967)
9. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P et al (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20:1892-1896 (Pubitemid 24031593)
10. Crestani B, Seta N, Palazzo E, Rolland C, Venembre P, Dehoux M et al (1994) Interleukin-8 and neutrophils in systemic sclerosis with lung involvement. Am J Respir Crit Care Med 150:1363-1367 (Pubitemid 24356653)
11. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK et al (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 3:e1452
12. Furuse S, Fujii H, Kaburagi Y, Fujimoto M, Hasegawa M, Takehara K et al (2003) Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 30:1524-1528 (Pubitemid 36835450)
13. Halloran MM, Woods JM, Strieter RM, Szekanecz Z, Volin MV, Hosaka S et al (1999) The role of an epithelial neutrophil-activating peptide-78-like protein in rat adjuvant-induced arthritis. J Immunol 162:7492-7500 (Pubitemid 29277729)
14. Imaizumi T, Albertine KH, Jicha DL, McIntyre TM, Prescott SM, Zimmerman GA (1997) Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. Am J Respir Cell Mol Biol 17:181-192 (Pubitemid 127499017)
15. Kim WU, Min SY, Cho ML, Hong KH, Shin YJ, Park SH et al (2005) Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther 7:R71-R79
16. Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD et al (1994) Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 94:1012-1018 (Pubitemid 24286441)
17. Kuroda K, Shinkai H (1997) Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 289:567-572 (Pubitemid 27477648)
18. Kwon JH, Keates AC, Anton PM, Botero M, Goldsmith JD, Kelly CP (2005) Topical antisense oligonucleotide therapy against LIX, an enterocyte-expressed CXC chemokine, reduces murine colitis. Am J Physiol Gastrointest Liver Physiol 289:G1075-G1083 (Pubitemid 41740613)
19. Le Y, Zhou Y, Iribarren P, Wang J (2004) Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cell Mol Immunol 1:95-104
20. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M (2010) Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 14:1241-1254
21. Masui Y, Asano Y, Shibata S, Noda S, Aozasa N, Akamata K et al (2012) Serum adiponectin levels inversely correlate with the activity of progressive skin sclerosis in patients with diffuse cutaneous systemic sclerosis. J Eur Acad Dermatol Venereol 26:354-360
22. Masui Y, Asano Y, Shibata S, Noda S, Akamata K, Aozasa N et al (2013) A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response. Rheumatology (Oxford) 52:1239-1244
23. Matsushita T, Hasegawa M, Hamaguchi Y, Takehara K, Sato S (2006) Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 33:275-284 (Pubitemid 43209303)
24. Noda S, Asano Y, Akamata K, Aozasa N, Taniguchi T, Takahashi T et al (2012) A possible contribution of altered cathepsin B expression to the development of skin sclerosis and vasculopathy in systemic sclerosis. PLoS One 7:e32272
25. Noda S, Asano Y, Takahashi T, Akamata K, Aozasa N, Taniguchi T et al (2013) Decreased cathepsin V expression due to Fli1 deficiency contributes to the development of dermal fibrosis and proliferative vasculopathy in systemic sclerosis. Rheumatology (Oxford) 52:790-799
26. Pickens SR, Chamberlain ND, Volin MV, Gonzalez M, Pope RM, Mandelin AM et al (2011) Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization. Angiogenesis 14:443-455
27. Schmidt K, Martinez-Gamboa L, Meier S, Witt C, Meisel C, Hanitsch LG et al (2009) Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients. Arthritis Res Ther 11:R111
28. Southcott AM, Jones KP, Li D, Majumdar S, Cambrey AD, Pantelidis P et al (1995) Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis. Am J Respir Crit Care Med 151:1604-1612
29. Taniguchi T, Asano Y, Akamata K, Aozasa N, Noda S, Takahashi T et al (2013) Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis. J Eur Acad Dermatol Venereol 27:747-753
30. Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D et al (2012) Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol 39:539-544
31. Toyama T, Asano Y, Takahashi T, Aozasa N, Akamata K, Noda S et al (2011) Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis. J Eur Acad Dermatol Venereol. [Epub ahead of print] PubMed PMID: 22211766
32. Yamada D, Asano Y, Takahashi T, Masui Y, Aozasa N, Akamata K et al (2012) Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis. Eur J Dermatol 22:351-357
33. Z'Graggen K, Walz A, Mazzucchelli L, Strieter RM, Mueller C (1997) The C-X-C chemokine ENA-78 is preferentially expressed in intestinal epithelium in inflammatory bowel disease. Gastroenterology 113:808-816
34. Zhou SL, Dai Z, Zhou ZJ, Wang XY, Yang GH, Wang Z et al (2012) Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma. Hepatology 56:2242-2254